Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Leap Therapeutics Announces $58.88M PIPE to Fund Pipeline, Kickstart Digital Asset Treasury
_↗ investors.leaptx.com
News Image

A significant financial and strategic shift was announced by Leap Therapeutics a biotechnology company specializing in targeted and immuno-oncology therapeutics, as it secured $58.88 million in cash commitments through a private investment in public equity (PIPE) offering prominently led by Winklevoss Capital., a biotechnology company specializing in targeted and immuno-oncology therapeutics, as it secured $58.88 million in cash commitments through a private investment in public equity (PIPE) offering prominently led by Winklevoss Capital.

This substantial funding is primarily dedicated to launching a novel digital asset treasury strategy, with Winklevoss Capital providing capital and strategic expertise to help Leap structure and execute the plan, aiming to build long-term shareholder value through active participation in digital assets. The PIPE encompasses the purchase of Units, priced at an aggregate of $0.61439 each, comprising 95,849,353 shares of common stock (or pre-funded warrants) and warrants to acquire an additional 71,887,008 shares.

Importantly, a portion of the capital will be used to continue the development of Leap's clinical pipeline, which includes the humanized monoclonal antibodies sirexatamab (DKN-01) and FL-501. Specifically, the press release highlighted that sirexatamab, which targets the Dickkopf-1 (DKK1) protein, recently completed a randomized controlled Phase 2 trial in colorectal cancer, with the results slated for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 on October 19 in Berlin, Germany.

As a condition of the lead investor agreement, Leap's Board of Directors will expand to 12 members, granting Winklevoss Capital the right to nominate two individuals, one of whom is expected to become the chairperson of the Board. The private placement, which was structured under exemptions from the registration requirements of the Securities Act of 1933 and was priced to satisfy Nasdaq's "Minimum Price" requirement, is anticipated to close around October 8, 2025.

Log In
Sign Up